NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Vera Therapeutics, Inc. (VERA) Stock Analysis

Vera Therapeutics, Inc. (VERA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VERA

$31.20

+$1.14 (+3.79%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VERA with… →

VERA Key Statistics

As of Oct 21, 2026
Trading
Open
$30.05
Previous Close
$30.06
Day's Range
29.85–31.57
52-Week Range
23.05–56.05
Volume
2.08M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$2.25B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.87
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$299.62M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.06M
1-Year Return
+2.87%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
2.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VERA closed at $31.20, +2.87% over 1 year.

Vera Therapeutics, Inc. (VERA) has a market capitalization of $2.25B.

In fiscal 2025, VERA reported revenue of $0.00.

VERA Stock Return by Calendar Year

Vera Therapeutics, Inc. (VERA) return since May 2021: what $10,000 became

1 year
$10,000 $10,287
+2.87%
5 years
$10,000 $18,852
+88.52%
Since May 2021
$10,000 $27,130
+171.30%

If you had invested $10,000 in Vera Therapeutics, Inc. (VERA) at the close on May 14, 2021, the earliest close on record here, it would have been worth $27,130 at the close on October 21, 2026: +171.30% in total, +20.15% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−38.39%
2025+19.74%
2024+174.97%
2023−20.52%
2022−27.58%
2021 (partial year)+132.35%

As of October 21, 2026.

VERA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$299.62M—
2024$0.00−$152.15M—
2023$0.00−$95.99M—
2022$0.00−$89.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$315.47M−$299.62M—
2024$0.00—−$167.17M−$152.15M—
2023$0.00—−$102.01M−$95.99M—
2022$0.00—−$90.90M−$89.06M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vera Therapeutics, Inc. (VERA) carries a market capitalisation of $2.25B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 361 employees.

The most recent close on file for VERA is $31.20, dated October 21, 2026. That is +$1.14 (+3.79%) against the previous close. The 52-week range on file runs from $23.05 to $56.05. The latest close sits 35.36% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $299.62M. Earnings per share on a trailing basis come to −5.87.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is +2.87%. Measured over 5 years, that is +13.52% a year compounded. Beta against the wider market is reported at 1.05. Annualized volatility over the trailing 5 years is 86.1%.

Growth & Income

No dividend is on file for VERA.

The strongest complete calendar year on file is 2024 at +174.97%; the weakest is 2022 at −27.58%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −38.39%.

Peer Comparison

Vera Therapeutics, Inc. (VERA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vera Therapeutics, Inc. VERA $2.25B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Vera Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Visit website →